GlassScriptPhysician profile
Barbara J Francis
NPI 1891903555
$8,932.66
in general payments reported to CMS, 2019-2025
48 companies · $1,960 in 2025
The $1,960 reported for 2025 was more than what 99% of Advanced Practice Midwife providers received nationally (typical 2025 total: $70.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,223 · 2022: $1,478 · 2023: $1,397 · 2024: $2,875 · 2025: $1,960.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,147 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,146.85 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $908.73 | 2021-2024 | |
| Teva Pharmaceuticals USA, INC. | $817.39 | 2021-2025 | Austedo Xr, Austedo Xr, Austedo |
| Exeltis, USA INC. | $550.70 | 2022-2024 | Slynd |
| Alexion Pharmaceuticals, INC. | $549.33 | 2022-2025 | Ultomiris |
| Neurocrine Biosciences, INC. | $531.04 | 2021-2025 | |
| Novo Nordisk INC | $472.94 | 2022-2024 | Wegovy |
| Inspire Medical Systems, INC. | $286.28 | 2023-2024 | Inspire |
| Sk Life Science, INC. | $256.69 | 2022-2025 | Xcopri |
| Jazz Pharmaceuticals INC. | $250.00 | 2024-2025 | |
| Sanofi-Aventis U.S. LLC | $245.05 | 2022-2025 | |
| Sage Therapeutics, LLC | $242.43 | 2024-2025 | Zurzuvae |
| Bayer Healthcare Pharmaceuticals INC. | $197.36 | 2021-2024 | |
| Acadia Pharmaceuticals INC | $188.22 | 2022 | |
| Amgen INC. | $175.76 | 2021-2023 | Prolia |
| Janssen Pharmaceuticals, INC | $175.32 | 2021-2024 | Xarelto |
Show all 48 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $173.88 | 2023-2025 | Veozah |
| Aimmune Therapeutics, INC. | $171.33 | 2025 | Zenpep |
| Otsuka America Pharmaceutical, INC. | $125.00 | 2024 | Rexulti |
| Urovant Sciences INC | $124.99 | 2022 | |
| Idorsia Pharmaceuticals US INC | $124.99 | 2023 | Quviviq |
| Bridgebio Pharma, INC. | $124.23 | 2025 | Attruby |
| Madrigal Pharmaceuticals | $124.04 | 2025 | Rezdiffra |
| Astrazeneca Pharmaceuticals LP | $123.03 | 2021-2023 | Andexxa |
| Vanda Pharmaceuticals INC. | $122.42 | 2025 | Ponvory |
| Axsome Therapeutics, INC. | $121.80 | 2024-2025 | Sunosi, Auvelity |
| Alnylam Pharmaceuticals INC. | $118.34 | 2025 | Amvuttra |
| Stryker Corporation | $116.12 | 2025 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Lilly USA, LLC | $114.81 | 2021-2024 | Mounjaro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $100.64 | 2022 | |
| Avadel Cns Pharmaceuticals, LLC | $98.74 | 2024 | Lumryz |
| Ipsen Biopharmaceuticals, INC | $90.95 | 2025 | Iqirvo |
| Corcept Therapeutics | $88.80 | 2021 | |
| Organon LLC | $88.76 | 2022-2024 | Nexplanon |
| Emd Serono, INC. | $88.63 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $86.37 | 2025 | Cobenfy |
| Abbott Laboratories | $84.37 | 2021 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $78.92 | 2022 | |
| Neurelis, INC. | $77.75 | 2024 | Valtoco |
| Biogen, INC. | $69.47 | 2023 | |
| Alkermes, INC. | $68.44 | 2023 | Lybalvi |
| Lexicon Pharmaceuticals, INC. | $66.08 | 2024 | Inpefa |
| Harmony Biosciences LLC | $63.54 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $60.82 | 2022 | |
| Amneal Pharmaceuticals LLC | $51.86 | 2022 | |
| Nevro Corp. | $49.91 | 2021 | |
| Silk Road Medical, INC. | $38.00 | 2024 | Enroute Transcarotid Neuroprotection System, Enroute Transcarotid Stent, Enroute Enflate Transcarotid Rx Balloon Dilatation Catheter |
| Biohaven Pharmaceuticals, INC. | $26.14 | 2021 | |
| Sanofi Pasteur INC. | $22.25 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barbara Francis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.